HIV-related cognitive impairment shows bi-directional association with dopamine receptor DRD1 and DRD2 polymorphisms in substance-dependent and substance-independent populations.
It has been postulated that drugs of abuse act synergistically with HIV, leading to increased neurotoxicity and neurocognitive impairment. The CNS impacts of HIV and drug use converge on the mesocorticolimbic dopamine (DA) system, which contains two main receptor subtypes: dopamine receptors 1 (DRD1) and 2 (DRD2). DRD1 and DRD2 have been linked to substance dependence; whether they predict HIV-associated neurocognitive disorder (HAND) is unclear. Using an advanced-stage HIV+ population, we sought to determine if drug dependence impacts the contribution of DA receptor polymorphisms on neurocognition. We observed that both DRD1 and DRD2 polymorphisms were associated with opiate and cocaine dependence (P < 0.05) in Caucasian subjects, but not African-American individuals. Using linear regression analysis, we examined the polymorphisms for associations with neuropsychological performance in global and cognitive domain T-scores (Motor, Processing Speed, Verbal Fluency, Learning, Memory, Executive Functioning, Working Memory) while controlling for opiate and cocaine dependency. In the Motor domain, we observed an association for two DRD2 polymorphisms (P < 0.05) in Caucasian subjects. The effects differed for substance dependence groups as the direction of the correlations with DRD2 were opposite to what was seen in subjects without these dependencies. In African-American subjects, associations were observed in nearly every domain, and again, the direction of the correlation differed between substance-dependent and substance-independent groups. We conclude that studies to examine genetic risk for HAND must carefully account for substance dependence patterns when assaying dopaminergic systems, as the neurobiological substrates of cognition in HIV populations may vary with tonic alterations secondary to chronic substance exposures.
Michelle M
MM
Jacobs
Jacinta
J
Murray
Desiree A
DA
Byrd
Yasmin L
YL
Hurd
Susan
S
Morgello
D000328:Adult; D001741:Black or African American; D019970:Cocaine-Related Disorders / Q000523:psychology; D003072:Cognition Disorders / Q000208:ethnology / Q000235:genetics* / Q000503:physiopathology / Q000523:psychology; D015331:Cohort Studies; D005260:Female; D015870:Gene Expression; D006678:HIV / Q000472:pathogenicity / Q000502:physiology; D015658:HIV Infections / Q000208:ethnology / Q000235:genetics* / Q000503:physiopathology / Q000523:psychology; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects; D008875:Middle Aged; D009483:Neuropsychological Tests; D009293:Opioid-Related Disorders / Q000523:psychology; D011110:Polymorphism, Genetic; D017447:Receptors, Dopamine D1 / Q000235:genetics* / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000235:genetics* / Q000378:metabolism; D012044:Regression Analysis; D012307:Risk Factors; D019966:Substance-Related Disorders / Q000208:ethnology / Q000235:genetics* / Q000503:physiopathology / Q000523:psychology; D013647:Task Performance and Analysis; D044465:White People
C583260:DRD1 protein, human; C581293:DRD2 protein, human; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2